摘要
目的分析阿莫西林克拉维酸钾干混悬剂+蒲地蓝消炎口服液,治疗小儿急性化脓性扁桃体炎(AST)的临床价值。方法患儿接收时段介于2021年1月-2022年2月,对50例小儿AST患儿实施规范分组操作;对照组23例阿莫西林克拉维酸钾干混悬剂,观察组27例联合蒲地蓝消炎口服液。结果经对临床疗效、不良反应进行评估,观察组分别为92.59%、3.70%,与对照组65.21%、26.08%结果展开比较,观察组临床疗效较高、不良反应较低(P<0.05)。经对临床症状消失时间、血清炎性因子进行评估,观察组与对照组结果展开比较,观察组临床症状消失时间较短,血清炎性因子水平较低(P<0.05)。结论阿莫西林克拉维酸钾干混悬剂+蒲地蓝消炎口服液,治疗小儿AST临床效果显著,具有推广和借鉴价值。
Objective To analyze the clinical value of amoxicillin-clavulanate potassium dry suspension+Pudilan Xiaoyan oral liquid in the treatment of acute suppurative tonsillitis(AST)in children.Methods The receiving period of the children was from January 2021 to February 2022,and standardized grouping operations were performed on 50 children with AsT;the control group was 23 cases of amoxicillin-clavulanate potassium dry suspension,and the observation group was 27 cases.Combined with Pudilan Anti-inflammatory Oral Liquid.Results After evaluating the clinical efficacy and adverse reactions,the observation group was 92.59%and 3.70%respectively.Compared with the results of 65.21%and 26.08%in the control group,the clinical efficacy of the observation group was higher and the adverse reactions were lower(P<0.05).After the evaluation of the disappearance time of clinical symptoms and serum inflammatory factors,the results of the observation group and the control group were compared.Conclusion Amoxicillin-clavulanate potassium dry suspension+Pudilan Xiaoyan oral liquid has a significant clinical effect in the treatment of children with AST,which has the value of promotion and reference.
作者
崔靖靖
Cui Jingjing(Department of Pediatrics,Guangrao Hospital of traditional Chinese medicine,Dongying,Shandong,257300,China)
出处
《中国医学文摘（耳鼻咽喉科学）》
2023年第5期6-8,5,共4页
Chinese Medical Digest(Otorhinolaryngology)
关键词
急性化脓性扁桃体炎
阿莫西林克拉维酸钾干混悬剂
蒲地蓝消炎口服液
疗效
不良反应
血清炎性因子
Acute suppurative tonsillitis
Amoxicillin-clavulanate potassium dry suspension
Pudilan Xiaoyan oral liquid
Efficacy
Adverse reactions
Serum inflammatory factors
